Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbilical Cord Derived Mesenchymal Stem Cells in Chronic Spinal Cord Injury
NCT01873547Phase 3Completed
- Sponsor
- The Third Medical Center of the Chinese People's Liberation Army General Hospital
- Start
- Jun 2012
- Primary completion
- Oct 2014
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of human umbilical cord mesenchymal stem cells in spinal cord injury (SCI) (3 arms), sponsored by The Third Medical Center of the Chinese People's Liberation Army General Hospital. Primary endpoint: International Standards for Neurological Classification of Spinal Cord Injury at 12 months. Started Jun 2012; status: completed.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT01873547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01873547.